Pharmvestnik, 22 August 2021
Since 2014, the pharmaceutical market has grown by 85% in value and reached 1.8 trillion roubles in 2020. In physical terms, last year the market attained the volume of 6.5 billion packages, which corresponds to the increase of 18% compared to 2014. Based on the AlphaRM data, Pharmvestnik analysed changes in the ranking of the leading companies of the Russian pharmaceutical market since 2014.
Pharmaceutical Market Dynamics
Sales of medicinal products (in roubles) have grown by 85% for seven years and reached 1.8 trillion roubles in 2020. Meanwhile, in physical terms, the last year's increase was significantly lower while amounting to +18% compared to 2014.
Source: AlphaRM
Over the seven years, the market has also grown quantitatively. According to AlphaRM, there were about 2,177 INNs of medicinal products in 2014, while in 2020 they reached 2,387. Accordingly, the number of brands and manufacturers has increased as well. In 2020 there were about 6,896 brands produced by 863 corporations on the market. Seven years earlier the number of brands was less by 976. The number of pharmaceutical companies has increased by 84.
Source: AlphaRM
Industry Leaders
The market sales of all of the top 10 companies except Teva have gone up significantly in value terms. Market leaders, Novartis and Bayer, have almost doubled their turnover compared to 2014, while the sales of Sanofi, the third-largest company, have increased by 26%.
For many years, there were no Russian companies among the leaders of the market. In 2020, the top 10 ranking included two Russian corporations. Pharmstandard has more than quadrupled its total value since 2014 and moved up to the 4th position of the ranking. OTC Pharm moved up to the 5th position of the 2020 ranking, while it held the 12th position just a year before.
The company's impressive growth has been bolstered by an increased demand for one of key medicinal products, Arbidol®, during the novel coronavirus disease pandemic. In the past year, this antiviral medication share constituted 30% of the manufacturer's portfolio, while in 2019 it only accounted for 8%. In a year, the product's sales have shown an almost six-fold increase.
Another Russian corporation, Pharmstandard, maintained its 2019 position and seems to have already taken one of the leading positions firmly while rising higher and higher in the ranking. The leading medicinal product in the company's portfolio in 2020 was Revlimid® (INN lenalidomide), which accounted for 24% of the company's total sales. The sales of Revlimid® went up 63% compared to 2019. Another driver of the company's growth was the immunosuppressant Elizaria®, which accounted for 14% of the company's portfolio in the past year.
Source: AlphaRM
<…>
Situation in the Current Year
In the first six months of 2021, Sanofi, who led the ranking in the first half of the last year, dropped down to the fourth position of the Top 10, while Novartis and Bayer moved up a position to the first and second lines of the ranking, respectively. Pharmstandard has risen even further, and it is currently the third in the ranking.
|
Top 10 Corporations on the Pharmaceutical Market by Value in H1 2021 |
|||||
|
Position |
Corporation |
Share of sales, % |
Sales growth, H1 2021 / H1 2020, % |
||
|
H1 2021 |
H1 2020 |
H1 2020 |
H1 2021 |
||
|
1 |
2 |
Novartis |
4.3 |
3.9 |
1.2 |
|
2 |
3 |
Bayer |
3.7 |
3.9 |
16.3 |
|
3 |
4 |
Pharmstandard |
3.6 |
3.8 |
16.0 |
|
4 |
1 |
Sanofi |
4.4 |
3.3 |
-14.7 |
|
5 |
5 |
Johnson & Johnson |
2.6 |
2.6 |
11.8 |
|
6 |
7 |
GSK |
2.5 |
2.4 |
10.0 |
|
7 |
16 |
Pfizer |
1.7 |
2.3 |
49.7 |
|
8 |
17 |
Roche |
1.7 |
2.3 |
51.2 |
|
9 |
8 |
Stada |
2.4 |
2.3 |
4.9 |
|
10 |
6 |
Abbott |
2.5 |
2.3 |
0.5 |
|
Source: AlphaRM |
|||||
<…>
| Back | Print out |
